CS Diagnostics Corp. (CSDX) 10% owner reports 104,507,800 common shares

Rhea-AI Filing Summary

CS Diagnostics Pharma GmbH filed an initial ownership report for CS Diagnostics Corp. (CSDX). The filing shows beneficial ownership of 104,507,800 shares of common stock held directly as of December 31, 2025, establishing the entity as a more than 10% shareholder.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider CS Diagnostics Pharma GmbH

Role 10% Owner

Type	Security	Shares	Price	Value
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 104,507,800 shares (Direct)

Footnotes (1)

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

CS Diagnostics Pharma GmbH

(Last) (First) (Middle)

1603 CAPITOL AVENUE, SUITE 413

(Street)

CHEYENNE WY 82001

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
12/31/2025

3. Issuer Name and Ticker or Trading Symbol
CS DIAGNOSTICS CORP. [ CSDX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	104,507,800	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Thomas Fahrhoefer	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does CS Diagnostics Corp. (CSDX) Form 3 disclose?

The Form 3 discloses that CS Diagnostics Pharma GmbH beneficially owns 104,507,800 shares of CS Diagnostics Corp. common stock. This is an initial ownership statement, confirming the entity as a significant, more than 10% shareholder as of December 31, 2025.

Who is the reporting person on the CS Diagnostics Corp. (CSDX) Form 3?

The reporting person is CS Diagnostics Pharma GmbH, an entity that is a more than 10% owner of CS Diagnostics Corp. The filing identifies it as the sole reporting person, with its holdings reported as directly owned common stock.

How many CS Diagnostics Corp. (CSDX) shares are reported on this Form 3?

The Form 3 reports beneficial ownership of 104,507,800 shares of CS Diagnostics Corp. common stock. These shares are listed as directly owned by CS Diagnostics Pharma GmbH following the reported date of December 31, 2025.

What type of security is reported in the CS Diagnostics Corp. (CSDX) Form 3?

The Form 3 reports ownership of CS Diagnostics Corp. common stock. CS Diagnostics Pharma GmbH lists 104,507,800 common shares as directly owned, with no derivative securities reported in the derivative securities table.

Does the CS Diagnostics Corp. (CSDX) Form 3 show direct or indirect ownership?

The Form 3 shows direct ownership. CS Diagnostics Pharma GmbH reports 104,507,800 shares of CS Diagnostics Corp. common stock with ownership form marked as “D,” indicating the shares are held directly rather than through an intermediate entity.

What is the event date reported on the CS Diagnostics Corp. (CSDX) Form 3?

The event date on the Form 3 is December 31, 2025. This date marks when the beneficial ownership position of 104,507,800 CS Diagnostics Corp. common shares, held by CS Diagnostics Pharma GmbH, is reported for regulatory disclosure purposes.